Empirical Bayes estimation of random effects of a mixed-effects proportional odds Markov model for ordinal data

Comput Methods Programs Biomed. 2011 Dec;104(3):505-13. doi: 10.1016/j.cmpb.2011.04.006. Epub 2011 May 26.

Abstract

The objective of this work was to investigate the factors influencing the quality of empirical Bayes estimates (EBEs) of individual random effects of a mixed-effects Markov model for ordered categorical data. It was motivated by an attempt to develop a model-based dose adaptation tool for clinical use in colorectal cancer patients receiving capecitabine, which induces severe hand-and-foot syndrome (HFS) toxicity in more than a half of the patients. This simulation-based study employed a published mixed-effects model for HFS. The quality of EBEs was assessed in terms of accuracy and precision, as well as shrinkage. Three optimization algorithms were compared: simplex, quasi-Newton and adaptive random search. The investigated factors were amount of data per patient, distribution of categories within patients, magnitude of the inter-individual variability, and values of the effect model parameters. The main factors affecting the quality of EBEs were the values of parameters governing the dose-response relationship and the within-subject distribution of categories. For the chosen HFS toxicity model, the accuracy and precision of EBEs were rather low, and therefore the feasibility of their use for individual model-based dose adaptation seemed limited.

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Bayes Theorem*
  • Capecitabine
  • Colorectal Neoplasms / drug therapy
  • Deoxycytidine / adverse effects
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / therapeutic use
  • Empirical Research
  • Fluorouracil / adverse effects
  • Fluorouracil / analogs & derivatives
  • Fluorouracil / therapeutic use
  • Hand-Foot Syndrome / etiology
  • Humans
  • Markov Chains*

Substances

  • Antineoplastic Agents
  • Deoxycytidine
  • Capecitabine
  • Fluorouracil